Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 8, 2026

A Unified Methodological Framework for Vestibular Schwannoma Research

A Unified Methodological Framework for Vestibular Schwannoma Research

Published on: June 20, 2017

Radiotherapy for Vestibular Schwannoma: Retrospective Cohort and Propensity Score Matching Analysis.

Vinicius de Carvalho Gico¹, Geovanne Pedro Mauro², Leila Maria Da Roz³

¹Department of Radiation Oncology, Instituto do Câncer do Estado de São Paulo, Medical School of Sao Paulo University, Sao Paulo, SP, Brazil.

Journal of Neurological Surgery. Part B, Skull Base

|May 7, 2026

Summary

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Late Recurrence After Angiographic Cure of Pediatric Arteriovenous Malformations Treated by Transvenous Embolization.

Operative neurosurgery (Hagerstown, Md.)·2026

Same author

LINAC-based Stereotactic Radiotherapy for Acromegaly: A Single-center Retrospective Cohort.

Journal of neurological surgery. Part B, Skull base·2026

Same author

Response to: "Letter to the Editor Regarding Cervical Spine Clearance in Adult and Pediatric Trauma: A Systematic Review".

The Journal of emergency medicine·2026

Same author

Hemodynamic modulation of transnidal pressure during transvenous arteriovenous malformation embolization: an experimental porcine model.

Journal of neurointerventional surgery·2026

Same author

Primary Clivus Bone Lesions.

Annali italiani di chirurgia·2026

Same author

Letter: Demarcation Line of Tissue Compaction in Traumatic Brain Herniation: A Conceptual and Clinical Model.

Neurosurgery·2026

Stereotactic radiotherapy (SRT) regimens for vestibular schwannomas (VS) show similar progression-free survival and toxicity. LINAC-based SRT offers flexible treatment options for VS, including in neurofibromatosis type 2 (NF2) patients.

Area of Science:

Neurosurgery
Radiation Oncology
Oncology

Background:

Vestibular schwannomas (VS) are often treated with surgery or stereotactic radiotherapy (SRT).
The optimal SRT regimen for VS treatment remains a subject of debate.
This study evaluates outcomes across various LINAC-based SRT techniques.

Purpose of the Study:

To compare the efficacy and safety of different stereotactic radiotherapy (SRT) regimens for vestibular schwannoma (VS) treatment.
To assess progression-free survival (PFS) and toxicity profiles of single-dose SRS, five-fraction SRS, and conventionally fractionated SRT.
To investigate the impact of neurofibromatosis type 2 (NF2) on treatment outcomes.

Main Methods:

Retrospective cohort study of 197 patients treated between 2008 and 2024 with LINAC-based SRT.

Keywords:

radiosurgery radiotherapy schwannoma stereotactic

Related Experiment Videos

Last Updated: May 8, 2026

A Unified Methodological Framework for Vestibular Schwannoma Research

A Unified Methodological Framework for Vestibular Schwannoma Research

Published on: June 20, 2017

Comparison of single-dose SRS (12-15 Gy), five-fraction SRS (25 Gy), and conventionally fractionated SRT (50.4 Gy).

Propensity score matching was employed to analyze progression-free survival (PFS) and toxicity, including hearing loss and facial palsy.

Main Results:

Overall lesion control was 89.8% by RECIST 1.1 criteria.
No significant difference in PFS was observed between different SRT regimens after propensity score matching (p=0.808).
New hearing loss occurred in 14.7% and facial palsy in 3.0% of patients; NF2 was associated with poorer PFS (p=0.002).

Conclusions:

Different LINAC-based SRT regimens demonstrate comparable outcomes in terms of lesion control and toxicity for VS patients.
SRT is a flexible and effective treatment modality for VS, even in patients with NF2.
Further prospective studies are warranted to confirm these findings.